1. DiMasi JA, Grabowski HG, Hansen RW. Costs of developing a new drug. Tufts Center for the Study of Drug Development Briefing. Innovation in the pharmaceutical industry: new estimates of R&D costs. 2014.
2. Getz K. Rising protocol complexity, execution varies widely by phase and TA. Tufts Center for the Study of Drug Development. Kaitin KI (ed). Impact Report 2010;12(3):1–4.
3. Getz K. Growing protocol design complexity stresses investigators, volunteers. Tufts Center for the Study of Drug Development. Kaitin KI (ed). Impact Report 2008;10(1):1–4.
4. Getz K. Nearly 60% of all protocols require amendments. One-third are avoidable. Tufts Center for the Study of Drug Development, Kaitin KI (ed). Impact Report 2011;13(5):1–4.
5. Kaitin KI. While total approvals decline, U. S. is preferred market for first launch. Tufts Center for the Study of Drug Development. Kaitin KI (ed). Impact Report 2008;10(6):1–4.